News
RANI
2.270
-3.40%
-0.080
Maxim Group Remains a Buy on Rani Therapeutics Holdings (RANI)
TipRanks · 2h ago
Rani Therapeutics' Weight-Loss Drugs Can Serve Specific Needs -- Market Talk
Dow Jones · 6h ago
Based on the provided financial report, the title of the article is: "RANI THERAPEUTICS HOLDINGS, INC. FORM 10-Q FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024
Press release · 1d ago
Rani Therapeutics GAAP EPS of -$0.24 in-line
Seeking Alpha · 1d ago
Rani Therapeutics Hldgs Q3 EPS $(0.24) Beats $(0.27) Estimate
Benzinga · 1d ago
Rani Therapeutics reports Q3 EPS (24c), consensus (29c)
TipRanks · 1d ago
*Rani Therapeutics 3Q Loss/Shr 24c >RANI
Dow Jones · 1d ago
*Rani Therapeutics: Runway To Fund Operations Into 3Q 2025 >RANI
Dow Jones · 1d ago
RANI THERAPEUTICS HOLDINGS INC: QTRLY LOSS PER SHARE $0.24
Reuters · 1d ago
RANI THERAPEUTICS Q3 OPERATING INCOME USD -11.799 MILLION
Reuters · 1d ago
Press Release: Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update
Dow Jones · 1d ago
Rani Therapeutics Holdings Inc <RANI.OQ> expected to post a loss of 26 cents a share - Earnings Preview
Reuters · 1d ago
Weekly Report: what happened at RANI last week (1104-1108)?
Weekly Report · 4d ago
Rani Therapeutics Holdings options imply 12.6% move in share price post-earnings
TipRanks · 11/08 18:35
Rani Therapeutics Holdings Inc <RANI.OQ> expected to post a loss of 26 cents a share - Earnings Preview
Reuters · 11/06 23:22
Weekly Report: what happened at RANI last week (1028-1101)?
Weekly Report · 11/04 10:42
Weekly Report: what happened at RANI last week (1021-1025)?
Weekly Report · 10/28 10:36
Rani Therapeutics: Innovative Oral Delivery System and Promising Obesity Treatment Potential Support Buy Rating
TipRanks · 10/22 19:45
Watching Rani Therapeutics; Zacks Small-Cap Research Gives Stock $12 Price Valuation
Benzinga · 10/22 17:04
Weekly Report: what happened at RANI last week (1014-1018)?
Weekly Report · 10/21 10:34
More
Webull provides a variety of real-time RANI stock news. You can receive the latest news about Rani Therapeutics Holdings, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RANI
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company is focused on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. It has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The RaniPill GO, is designed to deliver up to a three micrograms (mg) dose of drug with high bioavailability. The capsule includes a coating designed to withstand stomach acid but dissolve in the jejunum portion of the small intestine. Its pipeline includes RT-102, RT-105, RT-111 and RT-110. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC, which is intended to enable delivery of drug payloads up to 200uL in liquid form with high bioavailability.